5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.28▼ | 1.29▼ | 1.30▼ | 1.28▼ | 1.27▼ |
MA10 | 1.30▼ | 1.30▼ | 1.31▼ | 1.33▼ | 1.43▼ |
MA20 | 1.30▼ | 1.31▼ | 1.29▼ | 1.25▲ | 1.94▼ |
MA50 | 1.32▼ | 1.28▼ | 1.32▼ | 1.46▼ | 1.80▼ |
MA100 | 1.31▼ | 1.32▼ | 1.30▼ | 1.98▼ | 2.94▼ |
MA200 | 1.29▼ | 1.28▼ | 1.28▼ | 1.91▼ | 8.56▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.003▼ | -0.006▼ | 0.000▼ | 0.020▲ | -0.104▼ |
RSI | 23.481▼ | 38.900▼ | 41.965▼ | 43.500▼ | 37.539▼ |
STOCH | 25.000 | 13.230▼ | 24.252 | 43.972 | 17.772▼ |
WILL %R | -100.000▼ | -100.000▼ | -88.462▼ | -54.167 | -86.452▼ |
CCI | -193.447▼ | -131.901▼ | -118.048▼ | 1.737 | -69.909 |
Sunday, May 11, 2025 06:00 AM
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) released its financial results for the first quarter of 2025, alongside updates on its expanding immuno-inflammatory (I&I) pipeline and leadership ...
|
Friday, May 09, 2025 04:20 AM
The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The ...
|
Friday, May 09, 2025 04:00 AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
09/05/25 | 1.26 | 1.38 | 1.26 | 1.26 | 524,178 |
08/05/25 | 1.28 | 1.33 | 1.245 | 1.31 | 1,061,866 |
07/05/25 | 1.29 | 1.3046 | 1.20 | 1.25 | 583,346 |
06/05/25 | 1.27 | 1.28 | 1.22 | 1.28 | 1,069,936 |
05/05/25 | 1.44 | 1.45 | 1.28 | 1.28 | 384,003 |
02/05/25 | 1.40 | 1.455 | 1.37 | 1.44 | 668,869 |
01/05/25 | 1.38 | 1.3991 | 1.33 | 1.38 | 280,667 |
30/04/25 | 1.30 | 1.40 | 1.27 | 1.38 | 440,602 |
29/04/25 | 1.41 | 1.41 | 1.305 | 1.34 | 322,409 |
28/04/25 | 1.35 | 1.39 | 1.335 | 1.36 | 715,605 |
|
|
||||
|
|
||||
|
|